 NASHVILLE, Tenn., June 17, 2021 GLOBE NEWSWIRE -- Harrow Health, Inc. NASDAQ: HROW Harrow Health or the Company, an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of 20 million aggregate principal amount of 8.625 senior notes due 2026 the Notes, which includes the full exercise of the over-allotment option of 2.5 million aggregate principal amount granted to the underwriters. The Notes will be treated as a single series with the Companys outstanding 8.625 senior notes due 2026 and will trade interchangeably with the existing notes. 